Recombinant activated Factor VII for prevention and treatment of intraventricular haemorrhage in neonates

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:To assess the efficacy and safety of recombinant activated factor VII in the prevention or treatment of intraventricular haemorrhage in premature infants.The secondary objective is to perform subgroup analyses based on: dose (low versus high), frequency (4 versus 6 hourly) and duration (3 versus 5 days) of rVIIa; gestational age in the prevention (less than 26 weeks versus 26 weeks or more) and treatment (less than 26 weeks versus 26 weeks or more) studies; status of IVH (known or unknown) at enrolment in prevention studies.